DNA methyltransferase inhibitor exposure–response: Challenges and opportunities

DNA methyltransferase inhibitor exposure–response: Challenges and opportunities

Abstract Although DNA methyltransferase inhibitors (DNMTis), such as azacitidine and decitabine, are used extensively in the treatment of myelodysplastic syndromes and acute myeloid leukemia, there remain unanswered questions about DNMTi's mechanism of action and predictors of clinical response...

Full description

Bibliographic Details
Main Authors: Amanda B. Kagan, Dominique A. Garrison, Nicole M. Anders, Jonathan A. Webster, Sharyn D. Baker, Srinivasan Yegnasubramanian, Michelle A. Rudek
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13548

Internet

https://doi.org/10.1111/cts.13548

Similar Items